Symposium “Innovative & integrated solution providers in translational research to develop immunotherapies” (Paris, September 30th 2019)

Attend the 1st edition of the symposium dedicated to “Innovative & integrated solution providers in translational research to develop immunotherapies | Toward Next Generation of Solution Providers”, Maison de la Chimie, Paris (France).

This one-day workshop is co-organized by Cynbiose, Oncodesign, Aepodia and CERB.

More information and registration on this event that will take place on Monday September 30th, 2019 :

Registration is open!

Cynbiose attends the 2nd Antibody Industrial Symposium (AIS) in Tours.

Tours, June 24-25th, 2019 – Cynbiose will be attending the AIS congress ( whose topic is «Harnessing the Immune System with Therapeutic Antibodies».
The topics covered this year are:

  • Harnessing the Immune System with Immunomodulatory therapeutic Antibodies
  • Immunomodulation via cell membrane Antigens
  • Pitch Session Immunomodulation with mAbs : New Strategies & Technologies
  • Immunomodulation via Soluble Antigens
  • Immunomodulation via FC-FcgammaR interaction

Contact us to meet during the congress.

Cynbiose (FR) and Motac Neurosciences (UK, CN) sign a strategic partnership in metabolic disorders.

Lyon, January 8th, 2019 – Cynbiose SAS and Motac Neurosciences Ltd, two CRO specialised in preclinical services for the biopharmaceutical industry sign a strategic partnership to commercialize an integrated offer for exploratory and pharmacokinetics studies.

Both companies also agreed to co-develop innovative and proprietary preclinical models in metabolic disorders.

Contact us for more information.

Cynbiose attends the 2nd Immunotherapies for Infectious Congress (I4ID).

Lyon, December 10-11th , 2018 – The I4ID program is focusing on « Host-Directed Therapies (HDT) to fight infectious diseases ». HDT is a new emerging alternative approach to treat infectious diseases and overcome the problem of antimicrobial resistance and the lack of broad-spectrum virus-targeting drugs that we still encountered nowadays.

More information on

Cynbiose celebrates its 10th anniversary !

Lyon, November 2018 – Cynbiose thanks all employees and clients that have been a part of its rapid expansion and success !

Cynbiose attends the 2nd scientific workshop of the MARVELOUS project in the field of stroke and presents a scientific communication

Lyon, October 5th, 2018 – Cynbiose is part of the public-private consortium of the MARVELOUS project dedicated to « New MR imAging to pReVent cErebraL and myocardial reperfUSion injury », a new MRI technique for myocardial and cerebral infarction.

On this occasion, Cynbiose will present a scientifc communication entitled « Characterization of a new stroke model in non-human primate ».

The workshop theme will be dealing with Cerebral Vascular Accident and Acute Myocardial Infarction with discussions around imaging techniques, biomarkers, animal models and ischemia-reperfusion.

Members of the scientific advisory board, French research agency ANR representatives, academic research and clinical teams will be present.

More information on the MARVELOUS project :

Cynbiose granted a renewal of the AAALAC accreditation

Lyon, June 2018 – Cynbiose’s team is very pleased to share the renewal of the AAALAC accreditation status for the facility.

It rewards the collective commitment of Cynbiose’s staff in the development and continuous improvement of the animal care program, well beyond the regulatory constraints already particularly severe for primate species.
It also reflects the acknowledgement of Cynbiose’s ongoing commitment to ensure the quality of studies, both in service delivery and R&D, on models with a high scientific relevance to human health.

This accreditation represents an additional guarantee to its clients, sponsors and partners on the team’s epxertise and its commitment to scientific quality and animal welfare.

List of accredited facilities in France and Europe:

Cynbiose attends the workshop dedicated on « Preclinical developement of immunotherapies » in Lyon, April 2018

Lyon, April 2018 – Cynbiose will present a scientific cmmunication on « Relevance of non human primates models for the aerosolization of immunotherapies ».

This workshop is co-organized by MabDesign and the LyonBioPole cluster. It aims at crossing expertises on therapeutic areas and models specificities and predictivity for immunotherapies.

Cynbiose attends the 1st international congress on Immunotherapies for Infectious Congress (I4ID) in Lyon.

Lyon, December 11-12th , 2017 – Cynbiose has been selected by the scientific commitee to give a talk on « Preclinical development of immunotherapies for infectious diseases: relevance of the Non-Human Primate ».

During at the session dealing with « Innovation in diagnostics and immunotherapies for Infectious Diseases », the relevance of the NHP model in the preclinical development of immunotherapies, particularly in infectious diseases, will be detailled through several models developed by Cynbiose.

This international scientific congress is organized by Bioaster and MabDesign. The purpose of this congress is to foster interactions between pharmaceutical industries, research labs, service providers, and technology developers, and thus promoting the use of immunotherapies for prevention and treatment of infectious diseases.

More information on

Cynbiose attends the 1st national scientific meeting BioSimia in Paris, September 26-27th, 2017

BioSimia is a French biomedical research group specializing on NHP in different therapeutic areas as immunology, infectiology and neurosciences. The group gathers around 45 research teams belonging to internationally recognized French scientific research institutes as CNRS, INSERM, INRA and CEA.

This first annual meeting will be organized around multidisciplinary scientific presentations, open discussions and round tables. The main idea is to strengthen the link between Biosimia teams and set up concrete actions.

This meeting will bring together members of the BioSimia research group and other key players from national groups (COMPRIM of AFSTAL, EFOR, GIRCOR, etc.), industrial and private sectors.

Cynbiose by its unique positioning at the crossroads of the academic world and the pharmaceutical industry and by its many partnerships, has the honour to be invited to participate in this multidisciplinary scientific meeting.